Lymphoma in patients with asthma treated with dupilumab: much ado about nothing?
- PMID: 40998562
- DOI: 10.1183/13993003.01321-2025
Lymphoma in patients with asthma treated with dupilumab: much ado about nothing?
Conflict of interest statement
Conflict of interest: T.J. Davies declares no conflicts of interest. I.D. Pavord is a member of the European Respiratory Journal's International Advisory Board and reports honoraria for lectures, presentations or educational events from AstraZeneca, Aerocrine, Almirall, Sanofi/Regeneron, Menarini and GSK, payments for organising educational events from AstraZeneca, GSK and Sanofi/Regeneron, honoraria for attending advisory panels with Sanofi/Regeneron, AstraZeneca, GSK, Merck, Circassia, Chiesi, Upstream Bio and Areteia, and support for attending meetings from GSK, AstraZeneca and Sanofi/Regeneron.
Comment on
-
Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study.Eur Respir J. 2025 Sep 25;66(3):2500139. doi: 10.1183/13993003.00139-2025. Print 2025 Sep. Eur Respir J. 2025. PMID: 40537179
Publication types
LinkOut - more resources
Full Text Sources